Food Allergies
Completed Trials
A Phase 1, open label trial demonstrated the safety of Fecal Microbiota Transplants in peanut allergic patients. 30% of patients increased their amount of peanut protein they consumed without reaction.
A secondary trial was completed, including an antibiotic treatment prior to the administration of FMT. In this trial, 60% patients improved their peanut protein reactivity after one FMT.
Future trials are in planning to evaluate the efficacy of prolonged administration of FMT.
Achieving Cures Together is tax exempt pursuant to IRC Section 501(c)(3). Contributions are deductible to the extent allowed by law.
